April 5, 2020
  • 3:53 pm Fun Meal Prep Idea: Yellow-Colored Lunch Box
  • 3:53 pm Gilbert’s on Main serves New York Style Deli in Bellevue – KING 5 Evening
  • 3:53 pm Keto diet Meatballs with tomato sauce ASMR cooking No talking
  • 3:53 pm John’s Texas Tenderloin Roulade
  • 2:53 pm Why You Should Try “Cook Once Eat Twice” Meal Prep | What We Ate Over a Weekend (Healthy Recipes)

– So our first question to get started, how does ketosis and
Virta’s treatment affect heart health and cardiovascular risk? – Well, Catherine, that
is a really great question and one we get all the time. And the exciting news that I
have to share is we recently published a paper on this exact topic. So our paper looking at
our one-year results and cardiovascular outcomes
again was recently published, and I encourage everyone
to follow the link and read it for themselves, but
let’s talk about some of the really important highlights in the trial. So Catherine, of all the risk
factors that we looked at, and there were 26 altogether, the Virta treatment improved 22 of those. So from a big overview standpoint,
that’s pretty remarkable. But now let’s look a little
bit more at some of the granular details here about
things that patients are asking about. So one of the really important
things is that patients who have insulin
resistance, pre-diabetes or type II diabetes very often
struggle with something called atherogenic dyslipidemia, and let’s pause for a minute
and break that question down or break that term down. Atherogenic dyslipidemia means
essentially atherosclerosis causing cholesterol. And so what is this
atherogenic dyslipidemia? What it is is increased
triglyceride levels, decreased HDL or good
cholesterol and LDL particles that are very small and dense. This is really the hallmark
of atherogenic dyslipidemia, and once again important to
stress how very common it is in the insulin resistant
patient population. So what happened with atherogenic
dyslipidemia in our trial? Catherine, the results
were really remarkable. Triglycerides decreased by almost 25%, HDL or good cholesterol
went up by almost 20%, and those small dense
particles, what they did is they became large buoyant LDL particles. So it’s really important
also to note that there’s no medication that can do this. – Pretty awesome. – This is just by changing what? Your eating, can drastically
improve something that is a big cardiovascular risk
for this patient population. But one of the other
important things that we get questions about all the time is, I know that my diabetes may be reversed, and all these other
improvements may occur, but what’s gonna happen
to my LDL cholesterol? Well again, we looked at
this very specific question in our one-year cardiovascular
risk outcomes paper. And what happened? Well, LDLC or LCL cholesterol
did increase slightly. However, and this is really
important, when we look at cardiovascular risk factors
in a insulin resistant patient population, what
becomes a much better marker of risk when it comes to
LDL is LDL particle number. So how many LDL particles are there? Another term for this is the apoB. This is really looking at
how many particles there are that potentially could cause
problems with heart disease. And what we saw is that
these were unchanged through the year, and
that is really important. So the question that we
get asked all the time, I mean the really root question is, I can make all these other
things better like my diabetes, like my liver function numbers,
but am I making some of my cholesterol worse? And the answer from the paper is no. Again, the LDLP or apoB did
not change over the year, so that is a really
important take home point from the study. So that’s specifically
looking at cholesterol. So what we see is dramatic improvements in atherogenic dislipidemia,
no change in those really important LDLP or apoB
numbers, and we see a really big improvement in blood
pressure, a key risk factor for cardiovascular disease. And here’s the important point. Not only did we get to see
patients blood pressure significantly decrease,
but they were taking less medication for it. So we were making it
better while being able to remove medication, so again
a critical risk factor. The other one that is really
important to make note of is inflammation because it
is important for everyone to understand that at every
phase of the development of cardiovascular disease,
inflammation plays a key role. So what happens to the
inflammatory markers with any intervention is really important. And the best one to look at
specifically cardiovascular risk is one called C-reactive protein. And Catherine, in this
study our patients decreased their C-reactive protein by 40%. So again, another really
important cardiovascular risk factor made better
by the Virta treatment.

Randall Smitham